Review
In vivo studies of monoclonal anti-D and the mechanism of immune suppression

https://doi.org/10.1016/S1246-7820(01)00209-9Get rights and content

Abstract

Administration of anti-D immunoglobulin to D– women after delivery of a D+ infant has dramatically reduced the number of immunised women and cases of haemolytic disease of the fetus and newborn. The use of monoclonal anti-D might alleviate some of the pressures on maintaining adequate supplies of plasma sourced anti-D. Two human monoclonal antibodies, BRAD-3 (IgG1) and BRAD-5 (IgG3), with proven activity in in vitro functional (immunological) assays with cells bearing IgG Fc receptors (FcγR) were selected for clinical studies. They were prepared by purification of IgG secreted by culture of the Epstein-Barr virus-transformed B cell lines in hollow fibre bioreactors. The clearance of D+ red cells injected into D– subjects was accelerated by prior injection of the monoclonal antibodies, both individually and blended (3:1, BRAD-5: BRAD-3). The subjects were protected from Rh D immunisation. A large multicentre study evaluated the BRAD-3/5 blend for its ability to prevent Rh D immunisation in 95 D– subjects given 400 μg i.m. 24 hours after injection of 5 ml D+ red cells. Challenge injections of D+ red cells alone were given 24 and 36 weeks later, and blood samples were taken every 4 weeks from the subjects throughout the study for detection of anti-D responses. There was one definite and one possible failure of protection; in one subject the plasma anti-D level rose from week 12 onwards, and in another individual rapid seroconversion was observed at week 28. Considering the relatively large dose of red cells and the number of subjects studied, it was concluded that the failure rate was much lower than in routine Rh D prophylaxis. The responder rate was 13% by week 36 and 24% by week 48. The low percentage of responders and the modest levels of endogenous anti-D produced suggested that administration of monoclonal anti-D had induced long-term specific suppression of anti-D responses in these subjects. The most likely mechanism of action was considered to be inhibition of B cells resulting from co-crosslinking antigen receptors with inhibitory FcγR when the B cells contacted red cells that had bound passive anti-D.

References (45)

  • J.C. Cambier

    New nomenclature for the Reth motif (or ARH1/TAM/ARAM/YXXL)

    Immunol Today

    (1995)
  • C. Clarke et al.

    Decline in deaths from Rhesus haemolytic disease of the newborn

    J Roy Coll Physic Lond

    (1994)
  • S.B. Clarkson et al.

    Treatment of refractory immune thrombocytopenic purpura with an anti-Fcγ-receptor antibody

    New Engl J M

    (1986)
  • S.B. Clarkson et al.

    Blockade of clearance of immune complexes by an anti-Fcγ receptor monoclonal antibody

    J Exp M

    (1986)
  • Prevention of Rh-haemolytic disease: results of the clinical trial. A combined study from centres in England and Baltimore

    Br Med J

    (1966)
  • R.D. Davenport et al.

    IgG receptor roles in red cell binding to monocytes and macrophages

    Transfusion

    (1994)
  • V.J. Freda et al.

    Prevention of Rh isoimmunization. Progress report of the clinical trial in mothers

    JAMA

    (1967)
  • J. Goodrick et al.

    Plasma half-lives and bioavailability of human monoclonal Rh D antibodies BRAD-3 and BRAD-5 following intramuscular injection into Rh D-negative volunteers

    Clin Exp Immunol

    (1994)
  • B.D. Gorick et al.

    Relative functional binding activity of IgG1 and IgG3 anti-D in IgG preparations

    Vox Sang

    (1991)
  • H.H. Gunson et al.

    The primary Rh0(D) immune response in male volunteers

    Br J Haematol

    (1976)
  • A.G. Hadley et al.

    The chemiluminescent response of human monocytes to red cells sensitized with monoclonal anti-Rh(D) antibodies

    Clin Lab Haematol

    (1988)
  • A.G. Hadley et al.

    The functional activity of FcγRII and FcγRIII on subsets of human lymphocytes

    Immunology

    (1992)
  • Cited by (22)

    • Fc and Complement Receptors

      2015, Molecular Biology of B Cells: Second Edition
    • Rh-immunoglobulin: Rh prophylaxis

      2006, Best Practice and Research: Clinical Haematology
    • A single recombinant anti-RhD IgG prevents RhD immunization: Association of RhD-positive red blood cell clearance rate with polymorphisms in the FcγRIIA and FcγIIIA genes

      2004, Blood
      Citation Excerpt :

      These mechanisms would also not exclude a role for inhibition of specific B cells by FcγRIIB signaling once the RBCs are cleared from the circulation.60 The precise mechanism of action of Rh prophylaxis remains unclear and may depend on multiple additional pathways (reviewed in Kumpel20; Kumpel and Elson52; and Urbaniak and Greiss61). Our study has demonstrated that a single human recombinant IgG1 antibody expressed in CHO cells effectively prevented RhD immunization in male volunteers after a large RBC challenge of a volume not previously tested in other clinical trials of monoclonal anti-RhD antibodies.

    • Fc and Complement Receptors

      2004, Molecular Biology of B Cells
    View all citing articles on Scopus
    View full text